← All trials
NCT05129891
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 3, 2021
- Primary completion
- Sep 1, 2022
- Completion date
- Nov 11, 2022
- First posted
- Nov 22, 2021
- Last posted
- Nov 22, 2021
- Enrollment
- 384
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Novo NordiskLead sponsor
- Novo NordiskStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.